Worldwide, there remains significant unmet need in cancer treatment, with significant opportunities for companies who can develop safer and better targeted treatments.
Cancer affects more than 1 in 3 of the population and is increasing, partly due to population demographics and partly due to lifestyle factors. The majority of cancers seen are solid tumours (9 out of the 10 most prevalent). The four most prevalent cancers (53%*) are breast, lung, colorectal and prostate.
*(53% of all reported cancers in the UK according to CRUK statistics)
In 2007, oncology ranked as the fifth-largest therapeutic class worldwide but it has since grown steadily to become the largest segment, accounting for over 10% of total drug sales in 2015 – a trend that is anticipated to continue for the foreseeable future.
Total spending on cancer therapeutics and supportive care medicines reached $107 billion in 2015: this represents + 11.5% over 2014 and over the past five years on the global level an overall CAGR of 7.4%